MediSix Therapeutics
Cell Therapy for T-Cell Malignancies

MediSix is an early-stage cell therapy company developing novel applications of chimeric antigen receptor (CAR) T-cell immunotherapies for T-cell leukemias and lymphomas. These indications typically have a poor prognosis and treatment options are limited as they are not amenable to existing CAR-T therapies. Scientific founder Dario Campana is considered a pioneer in the cell therapy space and his work has been instrumental in the development of much of the technology that exists today.


University
National University of Singapore
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website